Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
SIBN gained 9.5% through August 25 as Q2 revenue rose 15%, adjusted EBITDA increased 178%, losses beat consensus, the physician base grew 19%, and management raised 2026 guidance.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Exceptional liquidity ⢠Persistent losses ⢠Weak cash flow SIBN has exceptional liquidity and modest leverage, but persistent losses, weak cash flow, accumulated deficits, and dilution risk make profitability improvement essential.
Price Behavior
Key Price Behavior Insights: ⢠Strong Uptrend ⢠Near-Term Resistance ⢠Elevated Momentum Support Level: $19.14â$19.48; secondary $18.04â$18.14 Resistance Level: $19.96â$20.00 Over the last month, SIBN surged about 20% to $19.96, with bullish momentum above $19.14 but elevated RSI near 69 signaling possible consolidation toward $18.14 if support fails.
Sentiment & News
Key News Insights: ⢠Revenue Accelerated ⢠Loss Narrowed ⢠Guidance Raised SI-BONE delivered strong Q2 2026 growth, improved profitability, and raised guidance, supporting a constructive outlook despite analysts' focus on estimate revisions.
AI Summary
SI-BONE is shifting from a cash-burning growth story toward potential operating leverage, but investors should treat the recent improvement as unproven and monitor sustained EBITDA expansion, positive free cash flow, and physician utilization before chasing the momentum-supported valuation.
Description
SI-BONE, Inc. is a medical device company that develops implantable products for musculoskeletal conditions affecting the sacropelvic anatomy in the United States and abroad. Its portfolio includes minimally invasive implants used in sacroiliac joint fusion and pelvic fracture repair, and it sells primarily through a direct sales force supplemented by distributors. The company was founded in 2008 and is based in Santa Clara, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 25 | Sep 1 | SIBN | SI-BONE, Inc. | SIBN gained 9.5% through August 25 as Q2 revenue rose 15%, adjusted EBITDA increased 178%, losses beat consensus, the physician base grew 19%, and management raised 2026 guidance. | Active | +0.0% |